Treatment of Nodal Non Hodgkin Lymphoma in West Africa: Experience of Institut Curie in Dakar

P. M. Gaye, A. A. Kassé, D. Diouf, M. M. Dieng, A. Dem

Dr Macoumba Gaye, Unité de Radiothérapie, Institut Curie, CHU Le Dantec, BP 15478 Fann, Dakar, Sénégal.

DOI: 10.4236/jct.2014.55054                

Abstract

In Senegal, few studies have been devoted to non-Hodgkin’s lymphoma. We conducted a retrospective descriptive study of 73 cases treated at the Institut J. Curie Hospital Aristide Le Dantec for non-Hodgkin’s lymphomas from 2001 to 2007. The main objective was to determine the clinical and therapeutic aspects. Our population consisted of 39 men and 34 women (sex ratio: 1.14). The average age was 36 years with extremes of 5 and 76 years. The most common locations were cervical (30.6%) and oropharynx (8.21%). Multiple locations were found in 30.6% of cases. Only 54.4% have histological exam. Patients were managed on cytology basis 42.6% of cases. Histology was performed in 39 patients (54.4%). Among these patients, 69% had aggressive lymphoma, of which 12.82% had a large B-cell lymphoma among indolent lymphomas (59%). The small cleaved cell lymphoma was most often found with 78.26% of cases. The patients were staged with insufficient tools. The protocol most often used was CHOP (64.3%). The most common complications reported were gastrointestinal (11%) followed by skin complications (8.2%). Radiotherapy was performed for 6 patients or 8.2% of cases. Therapeutic strategy was most often used as chemotherapy alone (69.9%). The median duration of follow-up is 18 months.

Keywords

Non Hodgkin Lymphoma, NHL, Africa

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Salles, G. and Coiffier, B. (1999) Lymphomes malins non hodgkiniens de haut grade de malignité. Cancers: évaluation, traitement et surveillance. 15.
[2]	Bah, E., parkin, D.M., Hall, A.J., Jack, A.D. and Whittle, H. (2001) Cancer in the Gambia: 1988-97. British Journal of Cancer, 84, 1207-1214. http://dx.doi.org/10.1054/bjoc.2001.1730
[3]	Belot, A., Grosclaude, P., Bossard, N., Jougla, E., Benhamou, E., et al. (2008) Cancer Incidence and Mortality in France over the Period 1980-2005. Revue d’Epidémiologie et de Santé Publique, 56, 159-175. http://dx.doi.org/10.1016/j.respe.2008.03.117
[4]	Schlaifer, D., Brousset, P. and Pris, J. (1997) Lymphome du sujet infecté par le VIH. Traité d’hématologie. 13-016-F-10, 9.
[5]	Elkacimi, S. (2009) Hémopathies malines à Dakar: Aspects épidémiologiques, clinques et thérapeutiques des hémopathies malines à la Clinique Médicale I du CHU Aristide Le Dantec de Dakar. Thèse Med Dakar. 143.
[6]	Fisher, R., DeVita, V., Hubbard, S., et al. (1983) Diffuse Aggressive Lymphomas: Increased Survival after Alternating Flexible Sequences of proMACE and MOPP Chemotherapy. Annals of Internal Medicine, 98, 304-309. http://dx.doi.org/10.7326/0003-4819-98-3-304
[7]	Frei, E. and Canellos, G.P. (1980) Dose: A Critical Factor in Cancer Chemotherapy. American Journal of Medicine, 69, 585-594. http://dx.doi.org/10.1016/0002-9343(80)90472-6
[8]	Oncolor (2006) Lymphomes malins non hodgkiniens. Référentiels. 11.
[9]	Thieblemont, C. and Coiffier, B. (2007) Lymphoma in Older Patients. Journal of Clinical Oncology, 25, 1916-1923. http://dx.doi.org/10.1200/JCO.2006.10.5957
[10]	Sweet, D., Kinzie, J., Gaeke, M., et al. (1981) Survival of Patients with Localized Diffuse Histiocytic Lymphoma. Blood, 58, 1218-1223.
[11]	Miller, T.P., Leblanc, M., Spier, C., et al. (2001) CHOP Alone Compared to CHOP plus Radiotherapy for Early Stage Aggressive Non-Hodgkin’s Lymphomas: Update of the Southwest Oncology Group (SWOG) Randomized Trial. Blood, 98, 724-730.
[12]	Miller, T.P., Unger, J.M., Spier, C., et al. (2004) Effect of Adding Rituximab to Three Cycles of CHOP plus Involved Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014) (Abstract). Blood, 104, 48-50.
[13]	Shikama, N., Ikeda, H., Nakamura, S. and Oguchi, M. (2001) Localized Aggressive Non-Hodgkin’s Lymphoma of the Nasal Cavity: A Survey by the Japan Lymphoma Radiation Therapy Group. International Journal of Radiation Oncology, Biology, Physics, 51, 1228-1233. http://dx.doi.org/10.1016/S0360-3016(01)01800-4
[14]	Miller, T.P. (2004) The Limits of Limited Stage Lymphoma. Journal of Clinical Oncology, 22, 2982-2984. http://dx.doi.org/10.1200/JCO.2004.05.926
[15]	Messori, A., Vaiani, M., Trippoli, S., et al. (2001) Survival in Patients with Intermediate or High Grade Non-Hodgkin’s Lymphoma: Meta-Analysis of Randomized Studies Comparing Third Generation Regimens with CHOP. British Journal of Cancer, 84, 303-307. http://dx.doi.org/10.1054/bjoc.2000.1566
[16]	Bauduer, F. (1998) Agents cytostatiques en hématologie. Encycl Med Chir, Traité d’Hématologie, 13-082-A-10, 22.
[17]	Advani, R., Rosenberg, S.A. and Horning, S.J. (2004) Stage I and II Follicular Non-Hodgkin’s Lymphoma: Long-Term Follow-Up of No Initial Therapy. Journal of Clinical Oncology, 22, 1454-1459. http://dx.doi.org/10.1200/JCO.2004.10.086
[18]	Mac Manus, M.P., Rainer Bowie, C.A. and Hoppe, R.T. (1998) What Is the Prognosis for Patients Who Relapse after Primary Radiation Therapy for Early-Stage Low-Grade Follicular Lymphoma? International Journal of Radiation Oncology, Biology, Physics, 42, 365-371. http://dx.doi.org/10.1016/S0360-3016(98)00233-8
[19]	Chen, M.G., Prosnitz, L.R., Gonzalez-Serva, A. and Fischer, D.B. (1979) Results of Radiotherapy in Control of Stage I and II Non-Hodgkin’s Lymphoma. Cancer, 43, 1245-1254. http://dx.doi.org/10.1002/1097-0142(197904)43:4<1245::AID-CNCR2820430412>3.0.CO;2-Z
[20]	McLaughlin, P., Fuller, L.M., Velasquez, W.S., Sullivan-Halley, J.A., Butler, J.J. and Cabanillas, F. (1986) Stage I-II Follicular Lymphoma: Treatment Results for 76 Patients. Cancer, 58, 1596-1602. http://dx.doi.org/10.1002/1097-0142(19861015)58:8<1596::AID-CNCR2820580803>3.0.CO;2-G
[21]	Peterson, B.A., Petroni, G.R., Frizzera, G., Barcos, M., Bloomfield, C.D., Nissen, N.I., Hurd, D.D., Henderson, E.S., Sartiano, G.P., Johnson, J.L., Holland, J.F. and Gottlieb, A.J. (2003) Prolonged Single-Agent versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B. Journal of Clinical Oncology, 21, 5-15. http://dx.doi.org/10.1200/jco.2003.05.128
[22]	Young, R.C., Johnson, R.E., Canellos, G.P., Chabner, B.A., Brereton, H.D., Berard, C.W. and DeVita, V.T. (1977) Advanced Lymphocytic Lymphoma: Randomized Comparisons of Chemotherapy and Radiotherapy, Alone or in Combination. Cancer Treatment Reports, 61, 1153-1159.
[23]	Schulz, H., Bohlius, J.F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M. and Engert, A. (2007) Immunochemotherapy with Rituximab and Overall Survival in Patients with Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 99, 706-714. http://dx.doi.org/10.1093/jnci/djk152
[24]	Genentech-Idec (2001) Rituxan Letter Warns of Fatal Mucocutaneous Reactions. The Pink Sheet. F-D-C Reports, 63, 32.
[25]	Davis, T.A., Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Williams, M.E., Weiner, G.J., Dowden, S. and Levy, R. (2000) Combination Immunotherapy of Relapsed or Refractory Low-Grade or Follicular Non-Hodgkin’s Lymphoma with Rituximab and Interferon-Alpha-2a. Clinical Cancer Research, 6, 2644-2652.
[26]	Foran, J.M., Rohatiner, A.Z., Coiffier, B., et al. (1999) Multicenter Phase II Study of Fludarabine Phosphate for Patients with Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenstrom’s Macroglobulinemia, and Mantle-Cell Lymphoma. Journal of Clinical Oncology, 17, 546-553.
[27]	Kalinka-Warzocha, E., Wajs, J., Lech-Maranda, E., Ceglarek, B., Holowiecki, J., Federowicz, I., Walewski, J., Czyz, J., Robak, T., Warzocha, K. and the Polish Lymphoma Research Group (2008) Randomized Comparison of Cladribine Alone or in Combination with Cyclophosphamide, and Cyclophosphamide, Vincristine and Prednisone in Previously Untreated Low-Grade B-Cell Non-Hodgkin Lymphoma Patients: Final Report of the Polish Lymphoma Research Group. Cancer, 113, 367-375. http://dx.doi.org/10.1002/cncr.23558